European Commission to investigate excessive drug pricing
Inquiry covers claims that Aspen Pharma’s price rises on five cancer treatments were unjustified
The European Commission has begun a formal inquiry into Aspen Pharma’s drug pricing practices. The move follows claims that the South Africa-based company inflated the price of five cancer treatments, and withheld medicines from some EU member states to impose unjustified price rises. It is the first time that the commission has officially investigated pricing practices for pharmaceuticals.